November 30, 2016
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Khanna discusses tocilizumab SSc extension trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WASHINGTON — At the American College of Rheumatology Annual Meeting, Dinesh Khanna, MD, rheumatologist and director of the scleroderma program at the University of Michigan, reviewed open-label extension data from the fasscinate trial. The trial was a phase 2 randomized controlled study of subcutaneous tocilizumab for patients with early systemic sclerosis (SSc) that was extended an additional 48 weeks from the initial 48-week period.
Khanna mentioned the following take-home messages from the trial:
- most patients who completed the first phase also enrolled in the extension;
- there were no unforeseen safety concerns;
- there were six events of serious infections in patients who transitioned from placebo to tocilizumab;
- patients reported improvements in both skin thickness and patient-reported outcome measures that achieved or exceeded the minimally important difference; and,
- patients who transitioned to tocilizumab showed no significant decline — with significance defined as 10% or more.
Khanna said researchers are enrolling patients for a phase 3 trial and data should be ready by early 2018.